文献速递淋巴瘤

荷兰1990-2015年青少年及青年霍奇金淋巴瘤生存改善与儿童持续高生存:一项基于人群的研究

Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015.
PubMed 文献 · Br J Haematol · 2020-02-06

该研究基于荷兰癌症登记数据,分析1990-2015年诊断年龄<25岁的2619例霍奇金淋巴瘤患者。儿童5年总生存早期已达93%,15-17岁和18-24岁患者5年总生存分别从1990-1994年的84%和90%改善至2010-2015年的96%和97%。治疗模式转向减少放疗、更多单纯化疗。

要点

  • 15-17岁和18-24岁患者5年总生存分别改善至96%和97%(2010-2015年)。
  • 儿童5年总生存早期已高达93%,治疗模式减少放疗、增加单纯化疗。

核心结论

  • 自1990年以来荷兰年轻霍奇金淋巴瘤患者的治疗取得显著进展,15-24岁患者生存大幅改善,儿童持续高生存。

研究设计与样本

  • 基于荷兰癌症登记的人群研究,纳入1990-2015年诊断年龄<25岁的2619例霍奇金淋巴瘤患者。

主要发现

  • 儿童5年总生存早期即达93%,15-17岁和18-24岁患者5年总生存分别从84%和90%(1990-1994年)改善至96%和97%(2010-2015年)。
  • 治疗模式转向减少放疗、更多单纯化疗,且因年龄组和分期而异;15-17岁患者越来越多在儿童肿瘤中心治疗。
  • 15-17岁患者生存不受治疗地点影响。

临床怎么用

  • 年轻霍奇金淋巴瘤患者治疗应关注减少放疗、增加单纯化疗的趋势,以平衡疗效与远期毒性。
  • 15-17岁患者可在儿童肿瘤中心或成人中心治疗,生存不受地点影响。

局限性

  • 本研究为基于人群的观察性研究,未报告具体的治疗方案细节、剂量及毒性数据。
  • 未提供多因素校正后的生存分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Population-based studies that assess long-term patterns of incidence, major aspects of treatment and survival are virtually lacking for Hodgkin lymphoma (HL) at a younger age. This study assessed the progress made for young patients with HL (<25 years at diagnosis) in the Netherlands during 1990-2015. Patient and tumour characteristics were extracted from the population-based Netherlands Cancer Registry. Time trends in incidence and mortality rates were evaluated with average annual percentage change (AAPC) analyses. Stage at diagnosis, initial treatments and site of treatment were studied in relation to observed overall survival (OS). A total of 2619 patients with HL were diagnosed between 1990 and 2015. Incidence rates increased for 18-24-year-old patients (AAPC + 1%, P = 0·01) only. Treatment regimens changed into less radiotherapy and more 'chemotherapy only', different for age group and stage. Patients aged 15-17 years were increasingly treated at a paediatric oncology centre. The 5-year OS for children was already high in the early 1990s (93%). For patients aged 15-17 and 18-24 years the 5-year OS improved from 84% and 90% in 1990-1994 to 96% and 97% in 2010-2015, respectively. Survival for patients aged 15-17 years was not affected by site of treatment. Our present data demonstrate that significant progress in HL treatment has been made in the Netherlands since 1990.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Reedijk AMJ, Zijtregtop EAM, Coebergh JWW, et al. Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015. Br J Haematol. 2020. PMID: 32030738. doi:10.1111/bjh.16491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。